Program
RSS0393
A development code. Also written as “RSS0393 ointment”, “RSS0393 ointment 0.03%” and “RSS0393 Ointment”.
In Jiangsu HengRui Medicine's pipeline, PDE 4
. Its studies are mostly in Psoriasis · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 43 open or running | phase 3since Apr 7, 2026 | Mar 24, 2025 | Jan 2027phase 3 · NCT07543224 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
RSS0393
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2025First study: phase 2 study in Psoriatic SubjectsFirst studyNCT06918743 · 147 planned
- Jul 29, 2025Phase 2 study in Plaque Psoriasis in ChildrenNCT07102888 · 20 planned · China
- Aug 28, 2025Phase 2 study in Atopic Dermatitis of AdultsNCT07158151 · 168 enrolled · China
- Apr 7, 2026Phase 3 study in Plaque Psoriasis SubjectsPhase 3 reachedNCT07543224 · 600 planned · China
Ahead
- Jan 2027Primary completion: phase 3 study in Plaque Psoriasis SubjectsNCT07543224
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07543224Plaque Psoriasis Subjects · China | 3 | Not yet recruiting | Jan 2027 | 600 |
| NCT07158151Atopic Dermatitis of Adults · China | 2 | Completed | Apr 10, 2026 | 168 |
| NCT07102888Plaque Psoriasis in Children · China | 2 | Not yet recruiting | Feb 2026 | 20 |
| NCT06918743Psoriatic Subjects | 2 | Not yet recruiting | Mar 2026 | 147 |
How it is read
Names in the registry
- “RSS0393 ointment”, 6 entries
- “RSS0393 ointment 0.03%”, 1 entry
- “RSS0393 Ointment”, 1 entry
Codes read as this program: RSS0393.
Conditions, from the studies’ own filings
- Psoriasis, 2 studies
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.